Entries by

Prioritization and selection of APIs using a risk-based approach

By Cristiana Cannata, PhD researcher in Environmental Science at Radboud University (Nijmegen, The Netherlands) & contributor of PREMIER WP1.2 There are more than 1500 active pharmaceutical ingredients (APIs) on the European market. Residues of these APIs can eventually reach the environment and given the enormous number of human medicines being used, it is unclear which […]

PREMIER contributes to the protection of soil

By Joan Tell, Director, EHS Risk Assessment at MSD Sunday December 5th is World Soil Day. This year 2021, it is focused on keeping soil alive and to protect soil biodiversity. Soil holds more than 25% of our planet´s biodiversity, from bacteria to slimy earthworms and is part of critical ecosystems processes on which humans […]

Ecotoxicity testing: guidelines and evaluation

By Alice Marshall, PhD researcher in Environmental Toxicology at University of York & contributor of PREMIER WP2.1; and Caroline Moermond, Sr Policy Advisor at the National Institute for Public Health and the Environment (RIVM), lead of PREMIER WP4 and contributor of WP3. With the continuous development of new and existing pharmaceuticals, investigation into the environmental legacy of active pharmaceutical […]

PREMIER Call for Data: data sources for the prioritization of APIs

One of the aims of the PREMIER project is to develop a framework to prioritise the environmental assessment of existing Active Pharmaceutical Ingredients (APIs). The prioritisation of APIs will follow a risk-based approach, where the predicted exposure concentration (PEC) is combined with an effect-based threshold (ETH), often represented by the Predicted No-Effect Concentration (PNEC). We […]

Meet our Scientific Advisory Board: Interview with Gerd Maack

Gerd Maack works at the German Environment Agency in the unit Environmental Risk Assessment of Pharmaceuticals. In this function he assesses the Environmental Risk Assessment of new pharmaceutical applications of Human and Veterinary Medicinal Products, often in close co-operation with other national competent authorities and also the European Medicinal Agency (EMA). He also serves as a […]

PREMIER aims to work synergistically with the main EU initiatives promoting environmental protection

The European Green week this year focuses on the EU ‘zero pollution ambition´ to promote a toxic-free environment. PREMIER aligns and contributes to the main European actions under the EU green deal which provides a legal framework for regulatory risk assessment requirements of pharmaceuticals. This year The European Green Week is held from the 31th […]

What are the needs of stakeholders regarding the environmental risk assessment of pharmaceuticals? Participate in our Survey!

The survey “Stakeholder needs and requirements regarding the environmental risk assessment of pharmaceuticals” is now online until the 19 July 2021!! If your work deals in some regard with pharmaceuticals in the environment, we would appreciate you taking some time (approx. 20-30 minutes) to let us know your organisation’s data and guidance needs. This way […]

The innovative PREMIER database: creating a robust architecture to deliver consistent environmental data to the community

The PREMIER project will deliver a novel database and digital assessment system (DAS) for characterising the environmental risks of medicines and making environmental data more visible and accessible to industry, academia, regulators and the public. By making this valuable knowledge available to the community, we will contribute to the responsible use of medicines. The PREMIER […]